Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.78
+2.3%		$1.45
$0.87
▼
$2.99
$126.12M-0.232.22 million shs1.54 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$147.78
-0.3%		$143.47
$57.90
▼
$160.81
$9.59B1.8491,120 shs598,117 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
0.00%-14.29%+31.82%+45.00%-9.84%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%+1.69%-4.46%+31.76%+151.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.78
+2.3%		$1.45
$0.87
▼
$2.99
$126.12M-0.232.22 million shs1.54 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$147.78
-0.3%		$143.47
$57.90
▼
$160.81
$9.59B1.8491,120 shs598,117 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
0.00%-14.29%+31.82%+45.00%-9.84%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%+1.69%-4.46%+31.76%+151.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
2.67
Moderate Buy$9.00405.62% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2.89
Moderate Buy$147.13-0.44% Downside

Current Analyst Ratings Breakdown

Latest BMEA and PTGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$153.00 ➝ $180.00
9/1/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$178.00 ➝ $190.00
8/31/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$175.00 ➝ $182.00
8/31/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/31/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/31/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$167.00 ➝ $170.00
8/24/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$112.00 ➝ $178.00
8/11/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C+)
8/10/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $170.00
8/10/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$118.00 ➝ $173.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$0.42 per shareN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$46.02M207.80N/AN/A$9.83 per share15.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$61.80M-$0.29N/AN/AN/AN/A-253.73%-97.91%11/3/2026 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$130.15M$1.03143.48N/AN/A29.40%12.03%11.23%11/5/2026 (Estimated)

Latest BMEA and PTGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.2235-$0.12+$0.1035-$0.12N/AN/A
8/5/2026Q2 2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$2.27$2.29+$0.02$2.29$212.03 million$213.48 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
3.47
3.47
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
21.71
21.71

Institutional Ownership

CompanyInstitutional Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%

Insider Ownership

CompanyInsider Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
10.60%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
5.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5072.48 million64.80 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
14164.71 million61.35 millionOptionable

Recent News About These Companies

California State Teachers Retirement System Raises Position in Protagonist Therapeutics, Inc. $PTGX
September 14 at 3:21 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-raises-position-in-protagonist-therapeutics-inc-ptgx-2026-09-14/
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX
September 13 at 4:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-buys-shares-of-11200-protagonist-therapeutics-inc-ptgx-2026-09-13/
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 7,278 Shares
September 11 at 6:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ptgx-insider-buying-and-selling-2026-09-11/
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX
September 11 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-24045-shares-of-protagonist-therapeutics-inc-ptgx-2026-09-11/
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $1,048,759.80 in Stock
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-protagonist-therapeutics-nasdaq-ptgx-ceo-sells-104875980-in-stock-2026-09-10/
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-protagonist-therapeutics-nasdaq-ptgx-ceo-sells-54174-shares-2026-09-10/
Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-dinesh-ph-patel-sells-63548-shares-of-protagonist-therapeutics-nasdaq-ptgx-stock-2026-09-10/
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944626-protagonist-therapeutics-inc-ptgx-presents-at-citigroups-biopharma-back-to-school-summit-2026
Protagonist Therapeutics authorizes $300M share repurchase program
September 8, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/protagonist-therapeutics-authorizes-300m-share-repurchase-program/ar-AA2bPtsj
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
September 8, 2026  |  accessnewswire.comA
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-protagonist-therapeutics-inc-nasdaq-ptgx-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-09-07/
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
September 6, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/protagonist-ptgx-swings-to-a-profit-as-two-drugs-near-blockbuster-status-1828514/
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
September 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mimrylo-approval-triggered-275m-payments-161422910.html
Q1 Earnings Estimate for PTGX Issued By HC Wainwright
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001905
BMO Capital Markets Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $190.00
September 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000042
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)
September 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PVLA/pressreleases/4389145/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-protagonist-therapeutics-ptgx/
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)
September 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4393175/analysts-are-bullish-on-these-healthcare-stocks-ascendis-pharma-asnd-protagonist-therapeutics-ptgx/
Research Analysts Offer Predictions for PTGX Q1 Earnings
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-research-analysts-offer-predictions-for-ptgx-q1-earnings-2026-09-02/
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
September 2, 2026  |  accessnewswire.comA
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News
September 2, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/protagonist-therapeutics-ptgx-stock-could-230701233.html
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/bull-case-protagonist-therapeutics-ptgx-121429906.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.78 +0.04 (+2.30%)
Closing price 04:00 PM Eastern
Extended Trading
$1.82 +0.03 (+1.97%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$147.78 -0.40 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$147.71 -0.07 (-0.05%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas